Subjective units of distress scale

ThreeD Capital Inc. Acquires Securities of Nirvana Life Sciences Inc.

Retrieved on: 
수요일, 6월 15, 2022
IDK, Joint, Company, Canadian Securities Exchange, Subjective units of distress scale, CSE, Ownership, Exercise, Investment, Acquisition, News, GLOBE, Security (finance), Nirvana, EarthBound

The Subject Shares represented approximately 1.4% of all issued and outstanding common shares of Nirvana.

Key Points: 
  • The Subject Shares represented approximately 1.4% of all issued and outstanding common shares of Nirvana.
  • Of this total, ThreeD held an aggregate of 3,000,000 common shares of the Company, representing approximately 9.1% of the issued and outstanding common shares of the Company on a non-dilutive and partially dilutive basis.
  • ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors.
  • The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

ThreeD Capital Inc. Acquires Securities of Bluesky Digital Assets Corp.

Retrieved on: 
수요일, 1월 12, 2022
IDK, News, Exercise, Joint, Subjective units of distress scale, Canadian Securities Exchange, GLOBE, Acquisition, Ownership, Company, CSE, EarthBound, Investment, Security (finance)

The Subject Shares represented approximately 3.2% of all issued and outstanding common shares of the Company as at January 7, 2022.

Key Points: 
  • The Subject Shares represented approximately 3.2% of all issued and outstanding common shares of the Company as at January 7, 2022.
  • The Subject Units were purchased through a private placement transaction and not through the facilities of any stock exchange.
  • ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors.
  • The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

ThreeD Capital Inc. Acquires Securities of ZeU Technologies Inc.

Retrieved on: 
수요일, 12월 22, 2021
Acquisition, CSE, IDK, Ownership, Exercise, News, National instrument, Investment, Subjective units of distress scale, Joint, EarthBound, Company, Canadian Securities Exchange, GLOBE, Cryptocurrency, Security (finance)

TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (ThreeD) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm that invests in disruptive companies and promising junior resources companies, announces that ThreeD acquired ownership and control of 250,000 common shares (the Subject Shares) and 250,000 common share purchase warrants (the Subject Warrants and together with the Subject Shares, the Subject Units) of ZeU Technologies Inc. (the Company or ZEU) on December 20, 2021 (the Acquisition).

Key Points: 
  • TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (ThreeD) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm that invests in disruptive companies and promising junior resources companies, announces that ThreeD acquired ownership and control of 250,000 common shares (the Subject Shares) and 250,000 common share purchase warrants (the Subject Warrants and together with the Subject Shares, the Subject Units) of ZeU Technologies Inc. (the Company or ZEU) on December 20, 2021 (the Acquisition).
  • The Subject Shares represented approximately 0.7% of all issued and outstanding common shares of the Company as of December 20, 2021.
  • ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors.
  • The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Retrieved on: 
수요일, 12월 1, 2021
Patient, GAD, Subjective units of distress scale, SUDS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Plasma protein binding, Anxiety, Safety, Anxiety disorder, Biomarker, ASX, Population, Screen for child anxiety related disorders, Benzodiazepine, Bionomics, Executive, PTSD, BNO, New Drug Application, Amygdala, Blood, Program, Social anxiety disorder, Communication, Study, NDA, Fast Track, Collection, OTCQB, SAD, FDA, Post-traumatic stress disorder, FOR, BNC210, Food, Pharmaceutical industry, Medical device

In November 2019, the FDA granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders.

Key Points: 
  • In November 2019, the FDA granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders.
  • NDA review usually does not begin until a company has submitted the entire drug application to the FDA.
  • BNC210 is an oral proprietary selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor in development for the acute treatment of SAD and chronic treatment of PTSD.
  • "Anxiety disorders are a significant burden for our communities and approximately 18 million adults suffer from Social Anxiety Disorder in the United States alone.

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

Retrieved on: 
월요일, 11월 1, 2021
Safety, SAD, GAD, Good clinical practice, BNC210, Blood, Anxiety, Contract research organization, Patient, CGMP, FDA, Benzodiazepine, Subjective units of distress scale, Food, GCP, PTSD, Amygdala, OTCQB, U.S. FDA, Adult, FOR, Post-traumatic stress disorder, BNO, CRO, Anxiety disorder, ASX, Social anxiety, Liebowitz social anxiety scale, IND, SUDS, Research, Executive, Good manufacturing practice, Food and Drug Administration, Population, Bionomics, Social anxiety disorder, Pharmaceutical industry

The PREVAIL Study is a randomised, double-blind, multi-centre Phase 2 clinical trial which will compare BNC210 to placebo on anxiety levels in patients with SAD during an anxiety-provoking behavioural task such as being asked to speak on a topic.

Key Points: 
  • The PREVAIL Study is a randomised, double-blind, multi-centre Phase 2 clinical trial which will compare BNC210 to placebo on anxiety levels in patients with SAD during an anxiety-provoking behavioural task such as being asked to speak on a topic.
  • Participants will be orally administered a single dose of study treatment approximately one hour prior to the behavioural task.
  • The primary objective of the study is to compare BNC210 to placebo on self-reported anxiety levels using the Subjective Units of Distress Scale (SUDS) during the behavioural task.
  • "Anxiety disorders are a significant burden for our communities and approximately 18 million adults suffer from Social Anxiety Disorder in the United States alone.

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Retrieved on: 
월요일, 9월 20, 2021
Blood, BNO, SAD, Clinical trial, OTCQB, Food, Investigational New Drug, Anxiety disorder, FDA, Subjective units of distress scale, Patient, Bionomics, BNC210, ASX, Absorption, Social anxiety disorder, FOR, IND, GAD, Benzodiazepine, Anxiety, SUDS, Pharmaceutical industry

BNC210 is an oral proprietary selective negative allosteric modulator of the 7nicotinic acetylcholine receptor in development for the treatment of anxiety and trauma- and stressor-related disorders.

Key Points: 
  • BNC210 is an oral proprietary selective negative allosteric modulator of the 7nicotinic acetylcholine receptor in development for the treatment of anxiety and trauma- and stressor-related disorders.
  • However, the slow absorption of the liquid suspension formulation of BNC210 and the requirement for it to be taken with food for optimal absorption, would limit its use in "real world" situations for the acute treatment of anxiety.
  • A new solid dose tablet formulation of BNC210 has been developed showing much improved and rapid absorption and we plan to use the tablet formulation for the Phase 2 acute treatment clinical trial in SAD patients.
  • "Anxiety disorders are a significant burden for our communities and approximately 18 million American adults suffer from Social Anxiety Disorder in the U.S. alone.